
Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for NW001
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Filed with SSE · Stock code 688321 · · 3 pages · Chinese
The announcement details the drug's basic information, including its application and the collaboration with Chengdu Chipscreen New Domain Biotechnology Co., Ltd. The filing also includes a risk warning regarding the lengthy and uncertain clinical trial process that may affect investor decisions.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for NW001
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix
Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.
Follow Shenzhen Chipscreen Biosciences